Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

It's likely to experience a lot of growth. As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (RXRX -3.56%) is a classic contender for being the kind of stock that can turn investors into millionaires. It has flashy technology and pioneering drug development methods. But can those really drive returns on the scale needed to make a relatively small investment grow to be worth millions? Buckle up and get ready for some calculations, be ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $8.19, demonstrating a -1.92% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.07%.Prior to today's trading, shares of the biotechnology company had gained 11.33% over the past month. This has outpaced the Medical sector's gain of 0.48% and the S&P 500's loss of 0.21% in t ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process.Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs.Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intell ...

文章核心观点 - Recursion Pharmaceuticals 正试图在人工智能(AI)革命和药物开发快速变化的格局中定位自己 [2] - 公司正试图整合一系列高度自动化的模块,以识别新药物候选物、验证它们并将最佳候选物推进临床试验 [5] - 公司正在利用AI、机器学习(ML)和大型语言模型(LLMs)等技术来减少人工劳动需求,并希望减少昂贵的人为错误 [5] - 公司声称其方法可以大大缩短从发现到临床试验的时间,并减少后期失败的情况 [5] 公司概况 - 公司目前有4个二期项目和1个一期项目,主要针对罕见疾病和罕见癌症 [6] - 公司目前还没有任何获批上市的产品,但已获得4600万美元的TTM收入,主要来自与其他生物制药公司的合作 [7] - 公司目前有2.963亿美元的现金和等价物,并正在进行2亿美元的股票发行 [7] - 公司未来18个月内将有多达7个临床试验结果公布,这是股价上涨的机会,但也存在下跌风险 [8] 投资风险 - 公司的技术平台尚未真正证明其声称的功能 [7] - 公司目标市场较小,复制成功可能很困难,因为罕见疾病的经验可能无法转移到其他领域 [10] - 如果公司的技术平台未能达到预期,股价可能会大幅下跌,并需要通过增发股票筹集更多资金 [11] - 对于风险厌恶型投资者来说,这可能是一个过于冒险的选择 [11] 投资机会 - 如果公司实现其最大化愿景,其当前的管线规模将只是一艘小船与超级油轮相比 [12] - 如果公司能够实现药物发现和开发过程的工业化,并大幅缩短时间线和成本,可能会成为该领域的领导者 [12] - 对于寻求巨大潜在收益的投资者来说,这可能是一个值得小额投资的机会 [12]

This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump.Recursion Pharmaceuticals (RXRX 8.85%) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development. Recursion Pharmaceuticals remains a small and little-known player in the industry, and like all clinical-stage biotechs, the stock is relatively risky. Ther ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,615 ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,61 ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $9.38, reflecting a +0.43% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%.The biotechnology company's shares have seen an increase of 1.97% over the last month, not keeping up with the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83%.The upcomin ...